新股暗盤 | 賽生藥業(6600.HK)暗盤段漲近6%
格隆匯3月2日丨賽生藥業(6600.HK)暗盤段快速拉昇,現報19.9港元,較發行價18.8港元漲5.8%。公司是一家擁有產品開發和商業化集成平台的生物製藥企業,2018年、2019年收益分別為14.08億、17.08億元人民幣,溢利分別為5.35億、6.14億元人民幣,每股有形資產淨值2.08-2.34港元。此次上市全球發售約1.16億股,其中香港發售5799.3萬股,國際發售5799.15萬股,每手500股,一手中籤率3%,香港發售股份獲1068倍認購,淨籌20.395億港元。太平資產管理(香港)等多家基石投資者已合共認購5513萬股,佔發售完成後已發行股本的約8.13%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.